Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · Real-Time Price · USD
2.000
-0.080 (-3.85%)
Sep 4, 2025, 11:10 AM - Market open

Phio Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
Cost of Revenue
3.593.646.337.018.893.72
Upgrade
Gross Profit
-3.59-3.64-6.33-7.01-8.89-3.72
Upgrade
Selling, General & Admin
3.863.744.374.454.635.08
Upgrade
Operating Expenses
3.863.744.374.454.635.08
Upgrade
Operating Income
-7.45-7.39-10.7-11.46-13.51-8.79
Upgrade
Interest Expense
---0.01---0
Upgrade
Interest & Investment Income
0.230.23----
Upgrade
Other Non Operating Income (Expenses)
0.130.010.01-0.02-0.01-
Upgrade
EBT Excluding Unusual Items
-7.09-7.15-10.7-11.48-13.52-8.79
Upgrade
Asset Writedown
---0.13---
Upgrade
Other Unusual Items
----0.23-
Upgrade
Pretax Income
-7.09-7.15-10.83-11.48-13.29-8.79
Upgrade
Net Income
-7.09-7.15-10.83-11.48-13.29-8.79
Upgrade
Net Income to Common
-7.09-7.15-10.83-11.48-13.29-8.79
Upgrade
Shares Outstanding (Basic)
310000
Upgrade
Shares Outstanding (Diluted)
310000
Upgrade
Shares Change (YoY)
590.92%240.15%83.32%6.30%179.70%-
Upgrade
EPS (Basic)
-2.52-9.08-46.76-90.91-111.84-207.04
Upgrade
EPS (Diluted)
-2.52-9.08-46.76-90.91-111.87-207.04
Upgrade
Free Cash Flow
-7.15-7.11-10.75-12.25-11.91-8.82
Upgrade
Free Cash Flow Per Share
-2.54-9.03-46.45-97.00-100.24-207.68
Upgrade
EBITDA
-7.44-7.39-10.64-11.39-13.44-8.72
Upgrade
D&A For EBITDA
000.060.070.080.07
Upgrade
EBIT
-7.45-7.39-10.7-11.46-13.51-8.79
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q